Wegovy vs. Ozempic
Wegovy and Ozempic both contain semaglutide and are GLP-1 receptor agonists, but their primary difference lies in their indications: Wegovy is approved for chronic weight management, while Ozempic is primarily for type 2 diabetes management. Both drugs work by slowing gastric emptying, reducing appetite, and improving blood sugar control. Wegovy delivers greater weight loss (approximately 15% bodyweight) compared to Ozempic's focus on HbA1c reductions and moderate weight effects. Wegovy has no additional off-label uses, whereas Ozempic is also used off-label for weight management. Both share common side effects like nausea and vomiting, with similar serious risks. However, Wegovy is significantly costlier, averaging $1,375/month compared to Ozempic's $875/month. Neither faces current shortages.
Slows gastric emptying, reduces appetite, and enhances feelings of fullness, leading to lower calorie intake. It also stimulates insulin release and reduces glucagon secretion, improving blood sugar control.
Common Side Effects
Nausea, vomiting, diarrhea, constipation, abdominal pain, headache, and fatigue.
Serious Potential Side Effects
Pancreatitis, gallbladder issues, kidney problems, and increased heart rate, thyroid cancer, anaphylaxis (or serious allergic reactions)
Slows gastric emptying, reduces appetite, and enhances feelings of fullness, leading to lower calorie intake. It also stimulates insulin release and reduces glucagon secretion, improving blood sugar control.
Common Side Effects
Nausea, vomiting, diarrhea, constipation, and abdominal pain.
Serious Potential Side Effects
Pancreatitis, gallbladder issues, kidney problems, and increased heart rate, thyroid cancer, anaphylaxis (or serious allergic reactions)